Avila, Clovis in cancer deal

Avila Therapeutics Inc. (Waltham, Mass) granted Clovis Oncology Inc. (Boulder, Colo.) exclusive, worldwide rights to develop and commercialize its EGFR mutant-selective inhibitor (EMSI) program. The oral small molecule, which targets the T790M mutant form of EGFR and the initial activating EGFR mutations, is in preclinical testing for non-small cell lung cancer (NSCLC). Phase I trials are slated to begin in 2012. ...